<DOC>
	<DOCNO>NCT02065232</DOCNO>
	<brief_summary>This pain survey study compare level discomfort experience breast cancer patient injection either technetium-labeled sulfur colloid technetium-labeled tilmanocept , FDA-approved agent use sentinel lymph node biopsy ( SLNB ) . Breast cancer patient already schedule SLNB part original surgical plan ask participate study randomize receive either technetium-labeled sulfur colloid technetium-labeled tilmanocept . After injection , patient complete pain questionnaire measure amount discomfort feel receive injection . There change patient 's treatment plan addition pain questionnaire . The investigator ' hypothesis patient feel less discomfort injection tilmanocept versus sulfur colloid .</brief_summary>
	<brief_title>Sentinel Lymph Node Mapping Post-Injection Site Pain</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>The patient diagnosis biopsyproven primary breast cancer diagnosis pure ductal carcinoma situ ( DCIS ) undergo intraoperative lymphatic mapping part standard surgical plan . The patient provide write informed consent participate study , his/her responsible caregiver , applicable . The patient candidate surgical intervention , lymph node map part surgical plan . The patient great 18 year age time consent . The patient performance status Grade 0 2 . The patient clinical negative node status time study entry . If patient child bear potential , patient negative pregnancy test within 72 hour prior administration radiopharmaceutical , surgically sterilize , postmenopausal least 1 year . The patient pregnant lactating . The patient clinical radiological evidence metastatic cancer include palpably abnormal enlarge lymph node</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>